12 results
Primary: Safety and tolerability of 2 dosages of ambrisentan. Secundary: Efficacy and PK.
We aim to investigate whether pulsatile flow in patients subjected to CPB preserves postoperative microcirculatory perfusion by prevention of a prothrombogenic profile and endothelial activation as are both present under non-pulsatile flow…
The primary objective of this study is to compare the two treatment strategies; first-line combination therapy (ambrisentan and tadalafil) versus first-line monotherapy (ambrisentan or tadalafil) in subjects with PAH. This will be assessed by time…
Primary: to assess the efficacy of ambrisentan 5mg after treatment period of 16 weeks, in subjects with inoperable CTEPH. Secondary: safety and tolerability.
Primary: to assess the longterm safety and tolerability of ambrisentan 5mg in subjects with inoperable CTEPH. Secondary: to collect supportive efficacy data.
Primary: Longterm safety and tolerability of 2 dosages of ambrisentan. Secundary: Supportive efficacy data.
We propose to conduct a study in healthy subjects where a serotonergic challenge is given in a placebo-controlled, crossover fashion. Before each challenge, participants will be measured 1 time to define their baseline resting state networks (RSNs)…
The objective of this study is to assess the effects of an increased NE level on the trade-off between exploitation and exploration. More specifically, this study will compare the exploitative/explorative behavior of participants who received either…
Primary Objectives:- To investigate the effects of a single dose (plasma concentration) 5-HTP challenge test (5-HTP200mg/CBD100+50mg/granisetron2mg) on hypothalamic fMRS activation patterns in healthy male volunteers.Secondary Objectives:- To assess…
Primary:1. To establish the effect of MCP on the release of plasma AVP and subsequent ACTH and cortisol secretion in the absence of a 5HTP-challenge.2. To establish the effect of MCP on the release of plasma AVP and subsequent ACTH and cortisol…
We propose to conduct a study in healthy young and elderly subjects and patients diagnosed with mild to moderate AD, FTLD, or DLB where cholinergic and serotonergic challenges are given in a placebo-controlled, crossover fashion. Before each…
Primary Objective: To evaluate the long-term safety (including progression to acute myeloid leukemia (AML) and/or other malignancies/pre-malignancies) of luspatercept in subjects who have participated in other luspatercept clinical trials.Secondary…